Podcasts about HIV

The Sunday after Magic Johnson announced his HIV-status, Jim Mitulski preached a sermon on being tired of people dying. We're sharing it as an interlude, a pause, and an immersion into one moment in AIDS' bleak midwinter.  For images and links about this episode visit https://www.heavenpodcast.org/interlude. In the sermon Rev. Mitulski refers to ARC. That means AIDS-Related Complex, a diagnostic category meant to indicate an earlier stage of HIV infection than AIDS. It was common in the period to hear references to both AIDS and ARC.  “Old Devil Time” is by Pete Seeger. The AIDS verses are by MCC San Francisco congregant Paul Francis.  You can see Magic Johnson's press release, announcing his HIV status here.  The biblical passage Rev. Mitulski is preaching on is John 11:1-44. Get more Outward with Slate Plus! Join for weekly bonus episodes of Outward and ad-free listening on all your favorite Slate podcasts. Subscribe from the Outward show page on Apple Podcasts or Spotify, or visit slate.com/outwardplus for access wherever you listen. When We All Get to Heaven is produced by Eureka Street Productions. It is co-created by Lynne Gerber, Siri Colom, and Ariana Nedelman. Our story editor is Sayre Quevedo. Our sound designer is David Herman. Our managing producer is Krissy Clark. Tim Dillinger is our consulting producer and Betsy Towner Levine is our fact-checker. We had additional story editing help from Sarah Ventre, Arwen Nicks, Allison Behringer, and Krissy Clark. For a complete list of credits, please visit https://www.heavenpodcast.org/credits. This project received generous support from individual donors, the Henry Luce Foundation (www.hluce.org), the E. Rhodes and Leona B. Carpenter Foundation, and California Humanities, a non-profit partner of the National Endowment for the Humanities (www.CalHum.org). Eureka Street Productions has 501c3 status through our fiscal sponsor FJC: A Foundation of Philanthropic Funds. The music for this episode is from the Metropolitan Community Church of San Francisco's archive. It was performed by MCC-SF's musicians and members with Bob Crocker and Jack Hoggatt-St.John as music directors. Additional music is by Domestic BGM.  Great thanks, as always, to the members and clergy of the Metropolitan Community Church of San Francisco who made this project possible.   Some links to good groups: AIDS Healthcare Foundation – provides medical care and support for people living with HIV/AIDS and preventative care for people at risk for contracting it.  The Magic Johnson Foundation – founded to address HIV/AIDS. Expanded to include education and community engagement.  San Francisco AIDS Foundation – a place to seek information about HIV.  POZ Magazine – a place to learn everything else about HIV (information included).Save AIDS Research – their recent, epic 24 hours to Save Research conference with all the latest HIV research is available on YouTube through this site. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Sunday after Magic Johnson announced his HIV-status, Jim Mitulski preached a sermon on being tired of people dying. We're sharing it as an interlude, a pause, and an immersion into one moment in AIDS' bleak midwinter.  For images and links about this episode visit https://www.heavenpodcast.org/interlude. In the sermon Rev. Mitulski refers to ARC. That means AIDS-Related Complex, a diagnostic category meant to indicate an earlier stage of HIV infection than AIDS. It was common in the period to hear references to both AIDS and ARC.  “Old Devil Time” is by Pete Seeger. The AIDS verses are by MCC San Francisco congregant Paul Francis.  You can see Magic Johnson's press release, announcing his HIV status here.  The biblical passage Rev. Mitulski is preaching on is John 11:1-44. Get more Outward with Slate Plus! Join for weekly bonus episodes of Outward and ad-free listening on all your favorite Slate podcasts. Subscribe from the Outward show page on Apple Podcasts or Spotify, or visit slate.com/outwardplus for access wherever you listen. When We All Get to Heaven is produced by Eureka Street Productions. It is co-created by Lynne Gerber, Siri Colom, and Ariana Nedelman. Our story editor is Sayre Quevedo. Our sound designer is David Herman. Our managing producer is Krissy Clark. Tim Dillinger is our consulting producer and Betsy Towner Levine is our fact-checker. We had additional story editing help from Sarah Ventre, Arwen Nicks, Allison Behringer, and Krissy Clark. For a complete list of credits, please visit https://www.heavenpodcast.org/credits. This project received generous support from individual donors, the Henry Luce Foundation (www.hluce.org), the E. Rhodes and Leona B. Carpenter Foundation, and California Humanities, a non-profit partner of the National Endowment for the Humanities (www.CalHum.org). Eureka Street Productions has 501c3 status through our fiscal sponsor FJC: A Foundation of Philanthropic Funds. The music for this episode is from the Metropolitan Community Church of San Francisco's archive. It was performed by MCC-SF's musicians and members with Bob Crocker and Jack Hoggatt-St.John as music directors. Additional music is by Domestic BGM.  Great thanks, as always, to the members and clergy of the Metropolitan Community Church of San Francisco who made this project possible.   Some links to good groups: AIDS Healthcare Foundation – provides medical care and support for people living with HIV/AIDS and preventative care for people at risk for contracting it.  The Magic Johnson Foundation – founded to address HIV/AIDS. Expanded to include education and community engagement.  San Francisco AIDS Foundation – a place to seek information about HIV.  POZ Magazine – a place to learn everything else about HIV (information included).Save AIDS Research – their recent, epic 24 hours to Save Research conference with all the latest HIV research is available on YouTube through this site. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Sunday after Magic Johnson announced his HIV-status, Jim Mitulski preached a sermon on being tired of people dying. We're sharing it as an interlude, a pause, and an immersion into one moment in AIDS' bleak midwinter.  For images and links about this episode visit https://www.heavenpodcast.org/interlude. In the sermon Rev. Mitulski refers to ARC. That means AIDS-Related Complex, a diagnostic category meant to indicate an earlier stage of HIV infection than AIDS. It was common in the period to hear references to both AIDS and ARC.  “Old Devil Time” is by Pete Seeger. The AIDS verses are by MCC San Francisco congregant Paul Francis.  You can see Magic Johnson's press release, announcing his HIV status here.  The biblical passage Rev. Mitulski is preaching on is John 11:1-44. Get more Outward with Slate Plus! Join for weekly bonus episodes of Outward and ad-free listening on all your favorite Slate podcasts. Subscribe from the Outward show page on Apple Podcasts or Spotify, or visit slate.com/outwardplus for access wherever you listen. When We All Get to Heaven is produced by Eureka Street Productions. It is co-created by Lynne Gerber, Siri Colom, and Ariana Nedelman. Our story editor is Sayre Quevedo. Our sound designer is David Herman. Our managing producer is Krissy Clark. Tim Dillinger is our consulting producer and Betsy Towner Levine is our fact-checker. We had additional story editing help from Sarah Ventre, Arwen Nicks, Allison Behringer, and Krissy Clark. For a complete list of credits, please visit https://www.heavenpodcast.org/credits. This project received generous support from individual donors, the Henry Luce Foundation (www.hluce.org), the E. Rhodes and Leona B. Carpenter Foundation, and California Humanities, a non-profit partner of the National Endowment for the Humanities (www.CalHum.org). Eureka Street Productions has 501c3 status through our fiscal sponsor FJC: A Foundation of Philanthropic Funds. The music for this episode is from the Metropolitan Community Church of San Francisco's archive. It was performed by MCC-SF's musicians and members with Bob Crocker and Jack Hoggatt-St.John as music directors. Additional music is by Domestic BGM.  Great thanks, as always, to the members and clergy of the Metropolitan Community Church of San Francisco who made this project possible.   Some links to good groups: AIDS Healthcare Foundation – provides medical care and support for people living with HIV/AIDS and preventative care for people at risk for contracting it.  The Magic Johnson Foundation – founded to address HIV/AIDS. Expanded to include education and community engagement.  San Francisco AIDS Foundation – a place to seek information about HIV.  POZ Magazine – a place to learn everything else about HIV (information included).Save AIDS Research – their recent, epic 24 hours to Save Research conference with all the latest HIV research is available on YouTube through this site. Learn more about your ad choices. Visit megaphone.fm/adchoices

Discover why Bangkok might be the ultimate city for men in 2026 as I sit down with a Western medical doctor living in Thailand to break down the real reasons so many guys are moving here. We talk about life in Bangkok, beyond just nightlife and redlight stereotypes, male loneliness, building a social life as an expat, and how the city can completely transform your health, fitness, and mindset. You'll hear a doctor's perspective on Thai healthcare, hair transplants in Bangkok vs Turkey and Europe, TRT and bodybuilding in Thailand, cosmetic procedures, stress reduction, and wellness culture. We also dive into the darker side: STDs in Thailand, party culture, “special massages,” HIV prevalence, and why proper testing and protection matter for anyone enjoying the “entertainment scene” in Bangkok. If you're thinking about traveling to Thailand, moving to Bangkok, dating Thai women, becoming an expat, or optimizing your health, this episode will give you an honest, unfiltered look at what life in Thailand can really be like for men in 2026.

Last month, a tragic incident took place in Jharkhand. Five children with thalassemia, an inherited blood disorder contracted HIV, following a blood transfusion. Initial investigations revealed that the blood they were given, was contaminated. While the Jharkhand government swung into action, suspending officials and announcing compensations – the fact remains that the blood that the children were given from a blood bank was unsafe. Blood is a critical compound – it is used across thousands of hospitals every day and there are regulations in place with regard to testing protocols to ensure that infected blood is not given to any patient. So where did the lapses occur? What kind of testing mechanisms do we have in place and are they sufficient? What is the ‘window period' when it comes to infections and how can this be shortened? And how do we ensure safe blood for every patient in need? Guest: Dr Rizwan Javed, transfusion medicine expert, Kolkata Host: Zubeda Hamid Edited by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., this new approach is set to revolutionize personalized medicine, particularly for genetic disorders where tailored interventions are crucial. Gene editing technologies, like CRISPR-Cas9, have opened unprecedented avenues for addressing genetic conditions directly at their source. However, the regulatory framework has struggled to keep pace with these advances, often hampering innovation with lengthy and complex approval processes.This proposed pathway seeks to streamline these requirements by adopting a risk-based assessment model that considers the unique properties of gene-editing therapies. Unlike traditional drugs, which follow a uniform clinical trial path, gene-editing treatments require a more nuanced regulatory approach due to their precision and potential off-target effects. The framework emphasizes adaptive trial designs—allowing for modifications based on interim results—and integrates real-world data to create a dynamic regulatory process. This not only promises faster development times but also fosters innovation by making it easier for companies to bring cutting-edge therapies to market.The implications are far-reaching. For researchers and biotech firms, this represents a chance to reduce time-to-market significantly while maintaining high safety standards. It also sets a precedent for future regulatory models that prioritize patient-centric approaches, acknowledging the diverse genetic landscapes of individuals with rare diseases. On a broader scale, this shift underscores the increasing recognition of personalized medicine's potential to transform healthcare delivery.In parallel developments, Gilead Sciences has achieved positive phase 3 results for its single-tablet regimen combining bictegravir and lenacapavir for HIV treatment. This milestone offers hope for simplifying treatment protocols for patients currently on multi-tablet regimens, potentially enhancing adherence and improving health outcomes. Gilead's preparation for regulatory filings marks an essential step forward in their therapeutic portfolio.Turning to cancer treatment advancements, Kyowa Kirin's collaboration with Kura Oncology has led to FDA approval for an oral medication targeting a subset of acute myeloid leukemia patients. This approval highlights the power of strategic partnerships in expediting the development of targeted cancer therapies and brings new hope to patients with limited treatment options.Meanwhile, several pharmaceutical companies, including Fresenius, Sun Pharma, and Teva, have been involved in product recalls ranging from hospital drugs to antibiotics and ADHD medications. These recalls underscore ongoing challenges in maintaining drug safety standards and emphasize the need for rigorous quality control measures across the industry.Zealand Pharma has opted to pause development of its dual GLP-1/GLP-2 agonist, dapiglutide, due to an increasingly crowded metabolic disorder treatment landscape. By reallocating resources towards programs with greater clinical differentiation potential, Zealand reflects broader industry trends prioritizing investments in areas with clearer paths to market success.In malaria treatment advances, Novartis has achieved significant progress with its next-generation drug 'Ganlum,Support the show

On the show David and Josh discuss the latest World, national and local HIV news

In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants

Where did the term slut come from and how has it been used for our gay community throughout our history? We discuss our varied history with sex, sexual freedom, HIV epidemic and how PrEP and Doxypep have changed the game on how we view sex and practice sex today. Reframing: the difference between validation-seeking sex and expansive, connected sex. Think back to a time you felt free after sex — not guilty, not anxious, but free. What was different about that experience? We discuss and share... Being a slut with intention — turning desire into a mindfulness practice Different types of Sluts: Tender, Curious, Sacred, Healing Hot Topic: Tish Hymann confronts a CA Senator as a Lesbian who says 'men' not Trans Women are using the bathroom and putting women in harms way... Hot Topic: Cheyenne Jackson says gay men are on the spectrum when it comes to 'gay voice'... Hot Topic: The tale of the Sniffies 'Bush' appreciator...we discuss deeper kinks... Advice: If you could tell your 30 year old self something what woudl it be? Advice: So you wanna meet up with a 'Dom' guy...what you should know and what to ask.... Thirst Trap: Which NSFW photo gets our pick and why... Follow Stevie on IG: @iam_stevev Follow Kodi on IG: @mistahmaurice Rate and Review us! Wanna drop a weekly or one time tip to TAGSPODCAST - Show your love for the show and support TAGS! Visit our website: tagspodcast.com Needs some advice for a sex or relationship conundrum? Ask TAGS! DM US ON IG or https://www.talkaboutgaysex.com/contact Follow Of a Certain Age on IG: @ofacertainagepod Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week, Marianna sits down with Carolyn Chu and Astha Kanani from the National Clinician Consultation Center (NCCC) to talk about treatment interruptions when it comes to HIV and Hepatitis C or HCV. Learn about why this can happen, the impact on treatment outcomes, and what you as an HIV care provider can do to prevent them. -- Reach out to the NCCC at 844-ASK-NCCC or 844-275-6222. Learn more at nccc.ucsf.edu. Resources mentioned in this episode: Dannenberg C, Matthews H, Hüfner A, et al.  Long-term real-world use of cabotegravir/rilpivirine: adherence and virological efficacy over a 44-month observation period.  Infect Dis Ther.  2025:14(8):1775-1797.De La Hoz A, Pooja A, Kancharla A, et al.  Characteristics and outcomes of direct-acting antiviral experienced patients with hepatitis C undergoing retreatment at an essential hospital in the United States.  Open Forum Infect Dis.  2024;11(12):ofae704.-- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

In this episode of the RCP Medicine Podcast, Dr Lisa Hamza, HIV and Sexual Health Consultant at St George's Hospital, London, joins Dr Rohan Mehra, Infectious Diseases and Microbiology Registrar, to explore the evolving landscape of HIV care. Together, they delve into the virology, history, and treatment of HIV, highlighting the remarkable progress made over the past four decades - from the early days of the epidemic to today's cutting-edge therapies and prevention strategies.Dr Hamza shares insights from her work as HIV Network Lead in South West London and co-chair of the HIV London Forum, discussing the challenges of stigma, late diagnosis, and health inequalities. The conversation also covers the UK's HIV Action Plan, the impact of opt-out testing, and the promise of long-acting treatments and pre-exposure prophylaxis (PrEP). This episode is a powerful reminder of how far we've come and how much further we must go to reach zero transmissions, zero deaths, and zero stigma.RCP Links Education Events Membership Improving care Policy and campaigns RCP Social Media Instagram LinkedIn Facebook X Bluesky Music: Episode 50 onward - Bensound.com Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas

A nemi úton terjedő betegségek szűrhetők és sok közülük kezelhető is. Ennek ellenére a stigma és a szégyen mellett a hiányos ellátórendszer is megnehezíti, hogy jelentősen csökkenjen a fertőzések száma. Dr. Tamási Béla bőr- és nemigyógyásszal beszélgettünk.See omnystudio.com/listener for privacy information.

No episódio desta semana, Tânia Vergara e Marcos Moura se juntam a Jordan Monteiro Pinheiro e Klinger Faico para um bate-papo imperdível sobre a trajetória da prevenção do HIV — do início da epidemia à chegada da PrEP injetável.Tânia compartilha histórias marcantes dos primeiros anos da AIDS no Brasil, as mudanças na abordagem clínica e o impacto das novas estratégias de prevenção.Uma conversa cheia de história, aprendizado e esperança para o futuro da infectologia.

On episode #93 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 10/23/25 – 11/10/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral High Prevalence of Varicella Zoster Virus Infection among Persons with Suspect Mpox Cases during an Mpox Outbreak in Kenya, 2024 (ASTMH: AJTMH) Earlier initiation of treatment following HIV acquisition reduces non-AIDS-defining malignancy risk (CID) TWiV 1267: A cancer vaccine and an mpox treatment (MicrobeTV) Cancers Caused by HPV (CDC: Human Papillomavirus (HPV)) Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection (Journal of the National Cancer Institute) Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine—A Systematic Review (Viruses) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices (ACIP)) HPV Vaccination Recommendations (CDC: Vaccines & Immunizations) Bacterial Consequences of Delaying Surgical Intervention in Patients with Native Joint Septic Arthritis (OFID) Fungal The Last of US Season 2 (YouTube) Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial (LANCET: Respiratory Medicine) Nasal Iodophor to Reduce Candidozyma auris Nasal Carriage in Nursing Home Residents (OFID) Epidemiology of Invasive Fungal Disease in Pediatric Heart Transplant Recipients (Journal of Pediatric Infectious Diseases Society) Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database (OFID) Genomic Dynamics of the Emergent Candida auris: Exploring Climate-dependentTrends (OFID) Parasitic Evaluation of a One Health public health program based on minimum inputs to control Taenia solium in Madagascar (PLoS Neglected Tropical Diseases) Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood (CID) Miscellaneous Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship(OFID) Plant-Based Diets and Climate Change, A Perspective for Infectious Disease Provider (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Dr. Azul DelGrasso is a Denver-based Romani scholar-practitioner, artist, and ceremonialist whose work bridges public health, ecopsychology, and psychedelic studies. With 28 years in STD/HIV capacity building and national training, Azul's research explores 5-MeO-DMT and unitive consciousness as pathways to healing and ecological identity. Rooted in the Southwest and guided by culture and resilience, he integrates rigorous scholarship, ethical facilitation, and creative practice to support individual and collective transformation.Resources on Roma in Mexico / Romani + Chicano cultural exchange:Los Gitanos en MexicoGitanos en MexicoMexico FlamencoEl Costumebre Lorenzo Armendariz5-MeO-DMT education resource: theconclave.infoFind Azul at https://www.azuldelgrasso.com/ and @ascendedvoicesOur Romani crush this episode are all the Romani writers and creators. You can book 1:1 readings with Jez at jezminavonthiele.com, and book readings and holistic healing sessions with Paulina at romaniholistic.com.Thank you for listening to Romanistan podcast.You can find us on Instagram, TikTok, BlueSky, and Facebook @romanistanpodcast, and on Twitter @romanistanpod. To support us, Join our Patreon for extra content or donate to Ko-fi.com/romanistan, and please rate, review, and subscribe. It helps us so much. Follow Jez on Instagram @jezmina.vonthiele & Paulina @romaniholistic. You can get our book Secrets of Romani Fortune Telling, online or wherever books are sold. If you love it, please give us 5 stars on Amazon & Goodreads. Visit https://romanistanpodcast.com for events, educational resources, merch, and more. Email us at romanistanpodcast@gmail.com for inquiries. Romanistan is hosted by Jezmina Von Thiele and Paulina StevensConceived of by Paulina StevensEdited by Viktor PachasWith Music by Viktor PachasAnd Artwork by Elijah VardoSupport the show

Joshua Barocas is an associate professor of medicine at the University of Colorado Anschutz Medical Campus. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.A. Barocas. The Erosion of Harm Reduction. N Engl J Med 2025;393:1865-1867. B.A. Barsky, A. Caplan-Bricker, and C. Robertson. Religious Liberty as a Shield for Public Health — The Case of Overdose-Prevention Centers. N Engl J Med 2025;393:1867-1869.

Send us a text

®Questo reportage racconta la drammatica realtà delle donne congolesi impiegate nel settore minerario artigianale, in un Paese segnato da guerre, sfruttamento e profonde disuguaglianze di genere.Nel Nord e Sud Kivu, regioni ricche di minerali preziosi, il gruppo armato M23 ha preso il controllo di importanti città, mentre il settore minerario continua a essere teatro di abusi. Dopo la chiusura della compagnia nazionale SOMINKI nel 1996, molte donne sono entrate nel settore artigianale, svolgendo lavori durissimi e pericolosi, spesso senza alternative.Tra queste c'è Furaha Myamungo, una “mama twangaise” di Kamituga, che racconta le condizioni disumane del lavoro: giornate interminabili, discriminazione, malattie respiratorie e HIV contratti per la polvere di quarzo e la miseria che spinge alla prostituzione.Nonostante tutto, emergono storie di resistenza e cambiamento. Emilienne Intongwa, minatrice e vedova, è riuscita a ottenere un proprio sito minerario e ha fondato l'associazione KOKA per tutelare le lavoratrici. Angelique Nyirasafari, ex operatrice umanitaria, è oggi una delle poche donne membro attivo di una cooperativa mineraria, impegnata a dare più diritti alle minatrici.Sebbene il sistema sia ancora profondamente maschilista e corrotto, mostra anche segnali di una lenta emancipazione femminile, fondamentale per cambiare il volto dell'industria mineraria in Congo.Prima emissione: 04 aprile 2025.

Stream this podcast to learn from experts Tessa Rife-Pennington, PharmD, BCGP, and Frank North, PharmD, MPA, DPLA, DASPL, how specialty pharmacists can apply practical strategies within different pharmacy settings to overcome barriers to PrEP use, especially among underserved patient subpopulations. Topics covered include:PrEP candidacy Selection of individualized regimensKey barriers to PrEP useStrategies for overcoming key barriers to PrEP accessEvolving state-based legislation on PrEP provision by pharmacistsModels of pharmacy-managed PrEPStrategies for addressing inequities in PrEP careComprehensive HIV prevention servicesPresenters:Tessa Rife-Pennington, PharmD, BCGPDr. Dawn K. Smith HIV Prevention Clinical FellowAmerican Academy of HIV MedicineVolunteer Assistant Clinical ProfessorUniversity of California, San Francisco, School of PharmacySan Francisco, CaliforniaFrank North, PharmD, MPA, DPLA, DASPLInstructional Assistant Professor, Irma Lerma Rangel College of PharmacyDirector of Learning in PracticeOffice of Interprofessional Practice, Education and ResearchTexas A&M University Health Science CenterPast President, National Pharmaceutical AssociationCollege Station, TexasLink to full program: https://bit.ly/49SLc0yGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Overview: In this episode, Toyin Nwafor, MD, and Christian B Ramers, MD, draw on their experience in primary care, HIV and HIV prevention to highlight missed opportunities for HIV prevention and discuss strategies to help address gaps in the HIV care continuum. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Toyin Nwafor, MD; Christian B Ramers, MD, MPH, FIDSA, AAHIVS   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References AIDSVu.org. Prevalence in the United States. 2022. Available from: https://map.aidsvu.org/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51. CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025). CDC. Discussing sexual health with your patients. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/sexual-history/index.html (Accessed June 25, 2025). CDC.gov. HIV diagnoses, deaths, and prevalence. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html (Accessed June 25, 2025). CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025). CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021 update: a clinical practice guideline. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025). Doblecki-Lewis S et al. J Int Assoc Provid AIDS Care 2019;18:2325958219848848. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025). HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025). HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed May 21, 2025). HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed July 18, 2025). HIV.gov. Who is at risk for HIV. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/who-is-at-risk-for-hiv (Accessed June 25, 2025). Johns Hopkins Bloomberg School of Public Health. What to know about PrEP. 2025. Available from: https://publichealth.jhu.edu/2025/who-needs-prep-for-hiv-prevention (Accessed June 25, 2025). Kamis KF et al. Open Forum Infect Dis 2019;6:ofz310. KFF. HIV testing in the United States. 2024. Available from: https://www.kff.org/hiv-aids/hiv-testing-in-the-united-states/ting in the United States | KFF (Accessed August 26, 2025). NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-infections-stis (Accessed June 25, 2025). Ramchandani MS et al. Curr HIV/AIDS Rep 2019;16:244–56. Saag MS et al. JAMA 2018;320:379–96. Sweeney P et al. J Acquir Immune Defic Syndr 2019;82(Suppl 1):S1–5. The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025). UNAIDS.org. Recommended 2030 targets for HIV. 2025. Available from: https://www.unaids.org/en/recommended-2030-targets-for-hiv (Accessed August 26, 2025). United States Census Bureau. National population by characteristics: 2020-2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025). United States Census Bureau. United States Population Growth by Region. 2025. Available from: https://www.census.gov/popclock/ (Accessed June 25, 2025). Yumori C et al. Sex Transm Dis 2021;48:32–6.

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH    For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus    References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

Overview: In this episode, Dr Melissa Jones and Dr Christian Ramers discuss the importance of pan-viral screening for HIV and hepatitis. They emphasize the need for integrated testing and prevention strategies and the current barriers to implementation. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Christian B Ramers, MD, MPH, FIDSA, AAHIVS; Melissa Jones, DNP, APRN-BC   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2025. Available from: https://www.hcvguidelines.org/ (Accessed June 10, 2025). Arora DR et al. ISRN AIDS 2013;2013:287269 Alter MJ. J Hepatol 2006;44:S6–9. Bazargan M, Cobb BMS, Assari S. Ann Fam Med 2021;19:4–15. Beard N, Hill A. Open Forum Infect Dis 2024;11:ofad666. Bottero J, Boyd A, Gozlan J et al. Open Forum Infect Dis 2015;2:ofv162. Brunetto, Maurizia Rossana et al. J Hepatol 2023;79:433–60. Calabrese SK, Krakower DS, Mayer KH. Am J Public Health 2017;107:1883–89. CDC. Status neutral HIV care and service delivery eliminating stigma and reducing health disparities. 2022. Available from: https://stacks.cdc.gov/view/cdc/129024 (Accessed June 10, 2025). CDC. Clinical guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 10, 2025). CDC. Clinical screening and diagnosis for hepatitis C. 2025. Available from: https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing (Accessed June 10, 2025). CDC. Clinical testing and diagnosis for hepatitis B. 2025. Available from: https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/  (Accessed June 10, 2025). CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 10, 2025). CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/ (Accessed June 10, 2025). CDC. Hepatitis A vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-a/vaccination/index.html (Accessed June 10, 2025). CDC. Hepatitis B vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-b/vaccination/index.html (Accessed June 10, 2025). CDC. HIV infection among heterosexuals at increased risk--United States, 2010. MMWR Morb Mortal Wkly Rep 2013;62:183-8. CDC. Viral hepatitis among people with HIV. 2025. Available from: https://www.cdc.gov/hepatitis/hcp/populations-settings/hiv.html (Accessed June 10, 2025. Clinical info HIV.gov. Considerations for Antiretroviral Use in People With Coinfections, Hepatitis B Virus/HIV Coinfection. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/hepatitis-b-virus-hiv-coinfection (Accessed July 21, 2025). Cornberg M, Sandmann L, Jaroszewicz J et al. J Hepatol 2025; doi: 10.1016/j.jhep.2025.03.018. Coukan F, Murray KK, Papageorgiou V et al. HIV Med 2023;24:893–913. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). GHTF. Breaking the silence: combating stigma and misinformation in the fight against hepatitis. 2024. Available from: https://www.globalhep.org/news-blogs/breaking-silence-combating-stigma-and-misinformation-fight-against-hepatitis (Accessed June 10, 2025) Grieb SM, Harris R, Rosecrans A et al. Ann Med 2022;54:138–49. HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 10, 2025). Kitt H et al. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. 2024. Available from https://www.gov.uk/government/statistics/hiv-annual-data-tables/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2024-report (Accessed June 10, 2025) Mayer KH, Agwu A, Malebranche D. Adv Ther 2020;37:1778–811. Mohareb AM, Larmarange J, Kim AY et al. Lancet HIV 2022;9:e585–e94. Moorman AC, Bixler D, Teshale EH et al. Public Health Rep 2023; doi: 10.1177/00333549231181348 Orkin, C. Open Forum Infect Dis 2024;11:ofad668. Post Z et al. Clin Liver Dis 2023;27:973-84 Saleska JL, Lee SJ. JAMA Pediatr 2020;174:1133–34. Symum H, Van Handel M, Sandul A et al. Prev Med Rep 2024;44:102777. UNAIDS. Global HIV & AIDS statistics — Fact sheet. 2025. Available from: https://www.unaids.org/en/resources/fact-sheet (Accessed July 18, 2025). UNM. Project ECHO. 2025. Available from: https://projectecho.unm.edu/ (Accessed June 10, 2025). Wejnert C et al. MMWR Morb Mortal Wkly Rep. 2016;65:1336–1342 WHO. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations (Geneva). 2022. Available from: https://www.who.int/publications/i/item/9789240052390 (Accessed June 10, 2025). WHO. Fact sheet: hepatitis A. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a (Accessed June 10, 2025). WHO. Fact sheet: hepatitis B. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (Accessed July 18, 2025). WHO. Fact sheet: hepatitis D. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d (Accessed June 10, 2025). WHO. Guidelines on HIV self-testing and partner notification: a supplement to the consolidated guidelines on HIV testing services. 2016. Available from: https://iris.who.int/handle/10665/251655 (Accessed June 10, 2025). WHO. Recommendations and guidance on hepatitis C virus self-testing. 2021. Available from: https://www.who.int/publications/i/item/9789240031128 (Accessed June 10, 2025). Xiao Y et al. Cells. 2020;9:2233

Overview: In this episode, Dr Toyin Nwafor and Dr Andrew Zolopa provide an overview of the HIV treatment landscape both globally and in the United States. They highlight the current gaps in the HIV care continuum, emphasize the importance of rapid start and viral suppression in reducing HIV transmission through sex and describe initiatives and strategies aimed at closing these gaps to help end the HIV epidemic in the United States. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Toyin Nwafor, MD; Andrew Zolopa, MD   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References AETC. Rapid (immediate) ART initiation and restart: guide for clinicians. 2023. Available from: https://aidsetc.org/resource/rapid-immediate-art-initiation-restart-guide-clinicians (Accessed June 25, 2025). Baxter A et al. J Acquir Immune Defic Syndr 2025;99:47–54. CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 25, 2025). CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025). CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/index.html#cdc_testing_why_get_tested-why-get-tested (Accessed June 25, 2025). CDC. Laboratory testing for the diagnosis of HIV infection. 2014. Available from: https://stacks.cdc.gov/view/cdc/23446 (Accessed June 25, 2025). CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025). Delaney KP et al. Am J Prev Med 2021;61(5 Suppl 1):S6–S15. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). HIV.gov. EHE overview. 2025. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview (Accessed June 25, 2025). HIV.gov. Global statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics (Accessed June 25, 2025). HIV.gov. HIV Care Continuum. 2025. Available from: https://www.hiv.gov/federal-response/other-topics/hiv-aids-care-continuum (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 25, 2025). HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 25, 2025). HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed June 25, 2025). Mirzazadeh A et al. PLoS Med 2022;19:e1003940. NIH. HIV testing. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-testing (Accessed June 25, 2025). Palacio-Vieira J et al. BMC Public Health 2021;21:1596. Saag MS et al. JAMA 2018;320:379–96. The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025). WHO. Supporting re-engagement in HIV treatment services: policy brief. 2024. Available from: https://www.who.int/publications/i/item/9789240097339 (Accessed June 25, 2025).

Overview: In this episode, Dr Gina Brown and Dr Sahar Khalili draw on their expertise in HIV prevention to provide an overview of the current PrEP landscape in the United States. They highlight advancements in HIV prevention and emphasize the importance of targeted programs to address disparities in access and uptake across population groups and geographic regions. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Gina Brown, MD; Sahar Khalili, PharmD   For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus  References ACOG. Preexposure prophylaxis for the prevention of human immunodeficiency virus. 2024. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/06/preexposure-prophylaxis-for-the-prevention-of-human-immunodeficiency-virus (Accessed June 25, 2025). ADAP Directory. About. 2024. Available from: https://adap.directory/about (Accessed June 25, 2025). Aidsmap. Condoms. 2023. Available from: https://www.aidsmap.com/about-hiv/condoms#toc-how-effective-are-condoms (Accessed June 25, 2025). AIDSVu. AIDSVu releases new PrEP data and launches PrEPVu.org, a new PrEP equity platform. 2024. Available from: https://aidsvu.org/news-updates/aidsvu-releases-new-prep-data-and-launches-prepvu-org-a-new-prep-equity-platform/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. AIDSVu releases 2024 PrEP use data showing growing use across the U.S. 2025. Available from: https://aidsvu.org/news-updates/aidsvu-releases-2024-prep-use-data-showing-growing-use-across-the-u-s/ (Accessed July 18, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. Location profiles: South. 2025. Available from: https://map.aidsvu.org/profiles/region/south/prevention-and-testing#1-2-PnR (Accessed July 31, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. PrEP use significantly associated with decreasing new HIV diagnoses across U.S. states. 2025. Available from: https://aidsvu.org/news-updates/prep-use-significantly-associated-with-decreasing-new-hiv-diagnoses-across-u-s-states/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51. Bekker LG et al. N Engl J Med 2024;391:1179–92. CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 2, 2025). CDC. Clinical Guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 25, 2025). CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025). Coates TJ et al. Lancet 2008;372:669–84. DHHS. Pre-exposure (PrEP) to prevent HIV during periconception, antepartum, ad postpartum. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/pre-exposure-prophylaxis-prep-prevent-hiv-perinatal.pdf (Accessed June 25, 2025). Gandhi RT et al. JAMA 2023;329:63–84. HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025). HIV.gov. Pre-exposure prophylaxis. 2025. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis (Accessed June 25, 2025). Kelley CF et al. N Engl J Med 2025;392:1261–76. Kourtis AP et al. Ann Epidemiol 2025:106:48-54. Landers S et al. Am J Public Health 2017;107:1534–35. Landovitz RJ et al. N Engl J Med 2021;385:595–608. NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-diseases-stds (Accessed June 25, 2025). NIH. HIV medicines during pregnancy and childbirth. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-medicines-during-pregnancy-and-childbirth (Accessed July 31, 2025) NIH. Post-exposure prophylaxis (PEP). 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/post-exposure-prophylaxis-pep (Accessed June 25, 2025). NIH. PrEP to prevent HIV and promote sexual health. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556471/ (Accessed June 25 2025). Siegler AJ et al. Ann Epidemiol 2020;45:24–31.e37 Sullivan PS et al. J Int AIDS Soc 2025;28:e26459. Townes A et al. Obstet Gynecol 2023;143:294–301. Underhill K et al. PLoS Med 2007;4:e275. United States Census Bureau. National population by characteristics: 2020–2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025). Owens DK et al. JAMA 2019;321:2326–36. Vermund SH et al. J Acquir Immune Defic Syndr 2013;63:S12–25. Washington State Department of Health. Pre-exposure prophylaxis drug assistance program (PrEP DAP). Available from: https://doh.wa.gov/you-and-your-family/illness-and-disease-z/hiv/prevention/pre-exposure-prophylaxis-drug-assistance-program-prep-dap (Accessed June 25, 2025). World Health Organization. Global HIV programme: pre-exposure prophylaxis (PrEP). Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis (Accessed June 25, 2025).

Chris delves into the case of Matthew Klein, a 43-year-old caught attempting to meet underage boys online. Using his expertise, Chris explores the troubling excuses predators, like Klein, give, such as loneliness and personal struggles. The episode uncovers Klein's dual life as a law firm receptionist and Uber driver, questioning his motivations and the potential harm he posed. Chris also discusses legal charges, including Klein's failure to disclose HIV status, and reflects on the influences behind his crime-fighting career. The episode concludes with audience interactions and Hansen's personal anecdotes.  Sponsored by:  TruthFinder.com. To get the answers you're looking for about the new people in your life, and to discover information on potential predators, go to www.TruthFinder.com/predators Home Title Lock: Go tohttps://hometitlelock.com/chrishansen and use promo code HANSEN to get a FREE title history report and a FREE TRIAL of their Triple Lock Protection! For details visit https://hometitlelock.com/warranty   Go to https://expressvpn.com/CHRISHANSEN and find out how you can get up to 4 extra months thanks to our sponsor, ExpressVPN! Dupe: Go to Dupe.com today and make your holiday shopping so much easier. It's 100% free to use. Stop overspending on gifts and start saving big this holiday season with Dupe.com Get your official Chris Hansen merchandise at https://haveaseat.dashery.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

-----Follow: Kecia Johnson IG: @IamKeciaJwww.IamKeciaJFoundation.org --Guest: Kecia Johnson author, Cancer & HIV warrior, Motivation Speaker, Educator

On a returning HOW DO YOU DO, FELLOW KIDS? (the world's finest Steve Buscemi-themed podcast) we're heading back to the past with Bill Sherwood's gay romantic drama PARTING GLANCES from 1986, featuring Steve Buscemi's breakout performance as Nick, an HIV-positive rock musician. Two straight dudes talking about a pioneering queer work? It happened! Now you can hear it and all the latest Steve Buscemi news. Enjoy! The post Episode 289 – How Do You Do, Fellow Kids? – Parting Glances (1986) first appeared on Cinema Smorgasbord.

Send us a Text Message about the podcastA five-day trek, a river that swallows missteps, and a video call that saves a mother and baby—this is what frontline HIV care looks like in Papua, Indonesia. We sit down with Dr. Agnela “Iggy” Chingwaro, an infectious disease physician from Zimbabwe, whose work braids medical expertise with faith, cultural humility, and stubborn hope. Her story exposes the hard truths behind late testing, the fear of national registration, and the maze of more than 300 local languages that shape how people understand illness, trust, and treatment.We unpack the crucial difference between HIV and AIDS, why “undetectable” means suppressed rather than cured, and how that nuance can make or break adherence. Dr. Iggy contrasts Africa's evolving HIV response with Papua's current challenges, where stigma keeps many away until opportunistic infections like TB and meningitis take hold. She details how government-supplied antiretrovirals, TB, and leprosy drugs still need community bridges—portable diagnostics, trained local educators, and clinics willing to meet people where they are. You'll hear how her team trains traditional midwives to screen pregnant women, uses telemedicine to coach emergency care, and partners with pilots and pastors to reach mountainside villages.The conversation turns deeply human: the adoption of a child orphaned by AIDS, the refusal of ambulance drivers to transport patients due to fear, and the practical ways to dismantle myths about transmission. We also shine a light on the “forgotten generation”—youth facing rising HIV rates alongside alcohol and drug abuse—and the vision for a safe, youth-friendly center that offers counseling, education, and dignity. This is global health at eye level: compassionate, persistent, and built on trust.If this moved you, help us grow the impact: subscribe, leave a rating, and share with a friend. Got thoughts or want to support Dr. Aggy's work? Email abovethenoise24@gmail.com and join the conversation.#HIV;  #AIDS;   #Papua  # Indonesia Leave reviewFollow and ShareSend Text Message New WebsiteBuy Me A Coffee Support the show#abovethenoise24# faith#reconciliation#race#racialreconciliationWe appreciate your support: Buy Me A CoffeeStay in touch: Email us at: abovethenoise24@gmail.com Facebook: @abovethenoise24 Instagram: abovethenoise24 Podcast art by Mario Christie.

On the show The 2nd part of Davids Interview with Ann Whatmore, talking about her experiences has a an HIV nurse in the 1980s and 90s in Brighton. A in-depth chat with Jordan Chan. Jordan's work as an LGBTQ+ activist and fundraiser, as well as the inspiration behind The Red Ribbon 2026 Calendar. A reminder you can order your calendar now at https://payhip.com/b/M5bjs . Follow Jordan on Instagram. .https://www.instagram.com/jordanwch_92/ HIV News and Great music too!

VOV1 - Nhiễm HIV qua đường tình dục ở tuổi vị thành niên là một nỗi đau âm thầm và dai dẳng. Đáng tiếc là những năm gần đây, ngày càng nhiều bạn trẻ phải đối mặt với cú sốc này.

Fisting used to be a niche fetish practiced by kinksters in dungeons, but today “Fisting is the It Girl” according to writer and expert fister Alexander Cheves. In this deep dive, Alex explains how the availability of fisting content on Twitter has led to a surge of interest from younger queer folks in recent years. But there’s a lot that first time fist fuckers need to know about how to prepare and train for play, in order to avoid serious injuries. Luckily, Alex has plenty of smart tips (and sweet stories) to share for both beginners and pros. Get the x-lube and puppy pads ready. It’s time to go Fisting For Compliments. Follow Sniffies' Cruising Confessions: cruisingconfessions.com Try Sniffies: sniffies.com Follow Sniffies on Social: Instagram: instagram.com/sniffiesapp X: x.com/sniffiesapp TikTik: tiktok.com/@sniffiesapp Follow the hosts: Gabe Gonzalez: instagram.com/gaybonez Chris Patterson-Rosso: instagram.com/cprgivesyoulife Guests featured in this episode: Alex Cheves: instagram.com/badalexcheves/See omnystudio.com/listener for privacy information.

On this episode of EquiTEA, Juan sits down with Dr. Carlos Calderon, Medical Director of the HIV/STD Early Intervention Program at Riverside University Health System- Public Health, for a powerful conversation in honor of National Latinx HIV & AIDS Awareness Day, observed Oct. 15. Together, they unpack the disproportionate impact of HIV on Hispanic/Latinx communities, spotlight the life-saving importance of testing and early detection and confront the stigma that continues to surround the virus. Resources: To get connected with HIV/STD resources, please visit: ⁠https://ruhealth.org/public-health/rivco-hiv-std-program

Untangle the hidden links between chronic inflammation, aging, HIV, and comorbidities. Credit available for this activity expires: 11/5/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003078?ecd=bdc_podcast_libsyn_mscpedu

Two-time Emmy and three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Dr. Schenta D. Randolph.

Two-time Emmy and three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Dr. Schenta D. Randolph.

Two-time Emmy and three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Dr. Schenta D. Randolph.

In this episode of Tank Talks, host Matt Cohen sits down with Roberto Bellini, Co-Founder of BSQUARED Capital and former CEO of Bellus Health, for a powerful conversation about family, legacy, and resilience in the world of biotech.Originally recorded just two weeks before the passing of his father, Dr. Francesco Bellini, one of the founding giants of Canadian biotech, this re-recorded episode serves as a moving tribute to the man known as “Mr. Biotech Canada.” Roberto opens up about what it was like growing up under the guidance of such a visionary figure and how that experience shaped his own path as an entrepreneur and leader.He reflects on the highs and lows of leading Bellus Health, from moments of near collapse to its remarkable $2 billion acquisition by GSK, sharing lessons on risk-taking, perseverance, and the importance of staying grounded through uncertainty. Roberto also offers his perspective on the future of Canadian biotech, highlighting the need for stronger late-stage funding and how BSquared Capital is helping to cultivate the next generation of innovators.This episode isn't just about business success; it's about honoring a legacy, learning through adversity, and discovering what it truly means to build something that endures.The Legacy of Dr. Francesco Bellini (00:02:52)* Francesco Bellini's incredible immigrant story: from arriving in Canada with nothing to a $6B biotech exit.* Business was the family's dinner table conversation, and attending AGMs as a child.* The founding of Biochem Pharma and the discovery of the groundbreaking HIV treatment.* “He was a visionary... he saw things before other people saw them.”Growing Up in Biotech (00:06:30)* Roberto's early memories of board meetings and dinner-table business lessons* How being “in the room” shaped his entrepreneurial mindset* Watching a $6B biotech deal become part of family historyThe Rise, Fall, and Rebirth of Bellus Health (00:08:27)* Roberto's journey from family office analyst to a 30-year-old, first-time CEO of a public company.* The devastating failure of the phase three trial for a rare kidney disease.* Inside a Biotech Failure: The intense, weekend-long “war room” process of unblinding clinical trial data and preparing for a public announcement.The Second Act: Finding the Cough Drug (00:13:47)* Discovering a promising molecule through the NeoMed Institute* Betting the company's future on a last-chance asset* Raising $20M when no one believed and turning it into a $2B successNegotiating the GSK Deal (00:24:45)* The strategic shift from “build-to-sell” to “build-to-scale”, positioning the company for a premium acquisition.* The M&A Playbook: Why you should never lead with a desire to sell; the importance of building for independence.* The high-stakes negotiation with GSK: going from an $11 offer to $14.75, almost losing the deal, and the “mellow tone” that saved it.* The entrepreneur's dilemma: “Every single entrepreneur I've met that sold their company, there's always a moment of not wanting to do it.”Building Canada's Biotech Future (00:30:11)* Why Canada has the innovation but lacks the enduring biotech giants.* The critical gap: The need for more late-stage capital and the role of Canadian pension funds.* The “Gilead of the North” vision: Creating a virtuous cycle of capital, entrepreneurs, and translational science.* Upcoming trends: The convergence of AI and drug discovery to de-risk development and lower costs.Beyond the Lab: Leadership, Risk, and Legacy (00:46:20)* Learning to embrace risk and find joy in reinvention* The best advice from Dr. B: “Spend your money, it'll make you want to earn more.”* Why true success isn't just building a company, but building peopleAbout Roberto BelliniFounder & Managing Partner, BSQUARED CapitalRoberto Bellini is a second-generation biotech entrepreneur and investor. As the former CEO of Bellus Health, he led the company's dramatic turnaround and eventual $2 billion acquisition by GSK. Drawing on his deep operational experience in drug development, he now co-manages BSQUARED Capital, a family office focused on investing in and supporting promising biotech ventures. He is a passionate advocate for building a stronger, more resilient biotech ecosystem in Canada.Connect with Roberto Bellini on LinkedIn: https://www.linkedin.com/in/robertobellini/Visit BSQUARED Capital Website: https://bsq-c.com/Connect with Matt Cohen on LinkedIn: https://ca.linkedin.com/in/matt-cohen1Visit the Ripple Ventures website: https://www.rippleventures.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit tanktalks.substack.com

Ashley James is a Master Practitioner and Trainer in Neuro-Linguistic Programming (NLP), Time Line Therapy, and holistic health coaching. She is host of the "Learn True Health" podcast.. She recently published "Addicted to Wellness", a book that guides you through a 12 week program promising a "total metamorphosis" in your approach to health.RESOURCES:This episode's Blog Page:https://drhaley.com/addicted-to-wellness/Buy "Addicted to Wellness" on Amazon:https://amzn.to/4oh1AMKVisit Ashley James's website :Learn True Health"https://learntruehealth.com/TIMESTAMPS:00:00 Intro Snip00:57 Introduce Ashley James02:40 Ashley's previous health challenges and how she overcame them06:48 Dr. Haley tells how he realized Diet Coke was causing tinnitis07:53 Ashley shares her soda healthy replacements09:20 Dr. Haley discusses the difference between medical care and alternative medicine10:40 Ashley discusses the parts of the Blood Type O diet that she likes11:27 Ashley James talks about her whole food plant based cooking program and gives some plant based diet tips13:45 Ashley explains how flu season is a lie and how is it actually candy (sugar) season15:28 Ashley did well from 6 years old until 13 when she rebelled by eating candy. What followed...19:20 Dr. Haley and Ashley James discuss the different diets and why diet dogma is bad22:07 Why you should ease into a big diet change and use the "crowding out" method23:00 Dr. Haley and Ashley discuss why plant foods are becoming more important in our diets24:20 Why do we need to detoxify and eat more fiber27:00 Why you should chew your food more29:32 What are post-biotics?32:54 What is the Food Mood Poop journal?36:20 What is the book "Addicted To Wellness"41:35 What really happens when you are dehydrated?44:45 What is the hydration challenge?48:40 How to get a free call with Ashley James49:30 What you get on the "Learn True Health Podcast"51:00 What do we know about aloe vera and HIV?53:20 How to Turn Off Anxiety

In episode 60 of Going anti-Viral, Dr Donald Abrams joins host Dr Michael Saag to discuss medical cannabis. Dr Abrams is a professor emeritus at the University of California San Francisco and a specialist in integrative oncology at the Osher Center for Integrative Health. Dr Abrams has studied complementary and alternative therapies, including mind-body treatments, botanical therapies, medical use of cannabis and herbal therapies used in traditional Chinese medicine. He continues to research the health effects of medical cannabis. Dr Abrams was previously at the forefront in HIV/AIDS research and treatment at San Francisco General Hospital and served as chief of the medical oncology service from 2003 to 2017. Dr Saag and Dr Abrams discuss the history of medical cannabis and the challenges Dr Abrams experienced in researching its use for medical therapy. They discuss the medical benefits of cannabis and the recommendations that clinicians may make as well as addressing the differences in products available including THC and CBD. They also discuss research in whether use of cannabis in young adults is related to schizophrenia. Finally, Dr Saag and Dr Abrams discuss the future of medical cannabis and whether physicians should continue to provide a role in its use, whether the scheduling of cannabis as a controlled substance will change, and the type of research that is needed to continue to explore where its use is beneficial. 0:00 – Introduction1:20 – Overview of the history of medical cannabis 4:10 – The fight for medical cannabis research and its use in people with AIDS 10:59 – Understanding the medical benefits of cannabis particularly for pain, insomnia, nausea, vomiting, anxiety, and depression 13:15 – How physicians navigate recommendations for the use of cannabis and the differences with the types of cannabis whether inhaled, digested, or tinctures 18:13 – CBD vs. THC: understanding the differences and other possible cannabinoid therapeutics23:25 – The role of physicians in the future of medical cannabis, the need for more research, and the overall availability for people who want it 25:57 – Overview of research if there a relationship between the use of cannabis and schizophrenia in young adults __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

What dangerous secrets lie beneath the "comforting newborn smell" of one of the most trusted companies in the world?In this explosive episode, Pulitzer Prize-nominated NYT journalist Gardiner Harris pulls back the curtain on Johnson & Johnson's history, detailed in his book No More Tears: The Dark Secrets of Johnson & Johnson.Gardiner reveals J&J's systemic deception, from knowingly selling asbestos-contaminated baby powder for seven decades to marketing drugs as cancer cures that were actually "Miracle Grow" for tumours. He exposes J&J's hidden role in the opioid crisis and their shocking refusal to share life-saving HIV drugs with Africa, costing millions of lives.Drawing from years of investigative reporting, Gardiner explains how corporate PR, media influence, and medical incentives allow giants like J&J to evade accountability, even with secret Grand Jury testimony as evidence. Tara and Gardiner also discuss the stories that didn't make it into the book and the mental toll of exposing the truth.Tune in for an essential, eye-opening conversation that forces consumers to question the products of a company they love and trust.Upcoming Bound RetreatsImmersive, one-of-a-kind literary experiences that take writers into the heart of India's most breathtaking landscapes.Wiling: A Weekend Writing Retreat | 28-30 November, 2025Learn more: https://boundindia.com/retreats/ Apply to all retreats: http://bit.ly/44TzYpY ‘Books and Beyond with Bound' is the podcast where Tara Khandelwal and Michelle D'costa uncover how their books reflect the realities of our lives and society today. Find out what drives India's finest authors: from personal experiences to jugaad research methods, insecurities to publishing journeys. Created by Bound, a storytelling company that helps you grow through stories. Follow us @boundindia on all social media platforms.

In the wake of one of the most intense hurricanes on record, Bill Gates wants you to know that climate change is no biggie.  Meanwhile, we might see HIV rates spike 49% in the next five years if planned cuts go ahead. That's roughly 75,000 new cases.  In that same vein, as more than 40 million people lose their food stamps, the money keeps flowing to Israel - that's the type of funding we just can't live without, government shutdown or no!  And of course, Israel is flaunting its untouchable status, violating the ceasefire literally hundreds of times. Gaza is still being decimated, murdered, starved.  And in Sudan, UAE-backed forces commit horrific acts of torture and murder as part of a coalition of US and Israeli interest in Sudan's natural resources.  Because ultimately, when the going gets tough, the empire goes back to its roots, as a dealer of doom.    leecamp.net artkillingapathy.com

 Have you ever wondered how a simple drive could turn into a scene straight out of a movie—complete with flat tires, chaos, and a mysterious ladder in the road? On this episode of The JB and Sandy Show, hosts JB and Sandy McIlree are joined by the ever-adventurous Tricia, who brings tales from Dallas that will leave you laughing, gasping, and itching to tune in. The episode opens with a lively discussion about streaming wars and the impact of the YouTube TV dispute with Disney, ABC, and ESPN—reminding listeners how quickly their favorite shows and games can disappear from their screens. But the real excitement begins when Tricia shares her wild weekend in Dallas, starting with a Romanian food festival (cabbage rolls, skinless sausage, and polenta, anyone?) and ending with a highway disaster that left at least 20 cars stranded with blown tires. Key Moments & Themes:Honky Tonk Festival Announcement: Austin Monthly launches its first annual Honky Tonk Fest, celebrating the city's iconic two-stepping venues like Jenny's Little Longhorn and The Broken Spoke. Tricia's enthusiasm for the festival and her legendary two-stepping partners add a personal touch to the local culture spotlight[1].Highway Mayhem: Tricia recounts a harrowing drive on I-30, where a rogue ladder caused a mass flat tire event. “Within five minutes, all of these cars were taken out on the side of the road. You got here is wrong place, wrong time.” The chaos, quick thinking, and camaraderie among strangers make for a gripping story[1].Romanian Festival Fun: From delicious food to unexpected gymnastics exhibitions and a vampire sighting, Tricia's night out is full of surprises. Her ability to turn any outing into an adventure is on full display.Drag Show Fundraiser: The episode wraps up with Tricia attending a drag show benefit for HIV research, highlighting the vibrant and supportive community spirit that defines Austin and Dallas alike.Memorable Quotes:“Squirming like a worm in hot ashes is what my grandma would say.” – Sandy“Within five minutes, all of these cars were taken out on the side of the road. You got here is wrong place, wrong time.” – Tricia“There's nobody I have two-stepped more with in my life than those two girls. Those two girls will drink the entire festival out of beer.” – Tricia Enjoyed the episode? Subscribe to The JB and Sandy Show, leave a review, and share this episode with friends who love wild stories and local flavor. Your support helps us keep bringing you the best of Austin, Dallas, and beyond!

In his weekly clinical update, Dr. Griffin and Vincent Racaniello ponder the nomination of Casey Means for Surgeon General by President Trump, how mRNA vaccines may enhance effectiveness of check point inhibitor cancer therapies, if viral infection associates with cardiac disease, H5N1 isolation from backyard birds and turkey farms, and the effectiveness of the COVID-19, RSV and influenza vaccines before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, if revaccination with the mRNA RSV vaccine is effective, how effective today's COVID-19 vaccine is for protection against severe disease following infection with current viral variants, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode The Challenge of Malignancies in HIV-1, Beyond Immune Activation and Back to Decreased Immune Surveillance (Journal of AIDS & Clinical Research) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1265: mRNA vaccines make cancer treatment great again (microbeTV: TWiV 1265) Viral Infections and Risk of Cardiovascular Disease (Journal of the American Heart Association) Confirmations of Highly Pathogenic Avian Influenza in Commercial and Backyard Flocks (USDA: Animal and Plant Health Inspection Service) Three large turkey farms in Minnesota hit with H5N1 avian flu (CIDRAP) Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 (NEJM) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles vaccine recommendations from NYP (jpg) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: Cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years (CID) Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England (LANCET: Infectious Diseases) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans (NEJM) Durability of 2024-2025 COVID-19 Vaccines Against JN.1 Subvariants (JAMA: Internal Medicine) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1266 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

In February, the Trump administration announced cuts to more than 90% of USAID’s foreign aid contracts and $60 billion in overall assistance around the world. In July, the agency’s remaining programs were brought under the control of the State Department. Thousands of USAID staff and contractors working in the US and around the world have been fired or laid off, including Portlander Leah Petit. A global health professional for nearly 20 years, Petit was a senior program advisor at USAID’s Office of HIV/AIDS when she lost her job in late January. Her projects focused on strengthening local health systems in Africa and Asia to sustain long-term HIV prevention, monitoring and treatment efforts.    In August, Petit embarked on a new career when she launched “Global Development Interrupted,” a podcast she hosts and produces featuring former USAID workers who help dispel misconceptions about the agency’s work overseas and how it has benefited Americans here. Established nearly 65 years ago, USAID has delivered lifesaving humanitarian assistance and medicines, mobilized to halt the spread of deadly diseases like Ebola, expanded access to clean drinking water and sanitation, along with countless other relief and development programs. Petit joins us to share more details about her podcast and what’s at stake when the US reverses its leadership on international aid, including the millions of lives that are expected to be lost with the dismantling of USAID.  

One in 4 people is infected with this silent killer disease that's deadlier than the plague. You may even have this infection! Find out about this deadly microbial threat and how to stay healthy so you don't become the next victim. 0:00 Introduction: Infectious disease deadlier than the plague 1:30 Latent infections 2:59 Tuberculosis facts 4:39 Tuberculosis and vitamin D7:38 Immune system function8:20 Sun exposure and infrared rays Many people are infected with a disease that's worse than the plague! The plague killed 200 million people, and in total, this bacterium has killed 1 billion! It's the world's deadliest infectious disease and kills more people than HIV and malaria combined. It kills around 1.3 million people each year, yet you don't hear much about it. Latent infections such as herpes, EBV, CMV, HPV, and Hepatitis B and C are able to go in and out of remission. Today, we're going to talk about the pathogen that gives you tuberculosis.Tuberculosis (TB) doesn't evade the immune system, it invades it. TB hides inside the macrophage, which is responsible for cleaning up bacteria and infections in the body. TB affects more people in the northern hemisphere away from the equator, and its incidence increases in the winter. Older people or those with type 2 diabetes, HIV, or low vitamin D are at an increased risk of an active TB infection. TB blocks the vitamin D receptor, which lowers your immune function. There was an uptick in TB outbreaks in the 80s when sun phobia was promoted. This campaign significantly reduced vitamin D levels by reducing sun exposure. Before the development of antibiotics, people with tuberculosis would go to sanatoriums for fresh air and sunlight exposure. Cod liver oil was also shown to be beneficial for people with tuberculosis infections.The immune system destroys TB with a compound called cathelicidin, a broad-spectrum antimicrobial that depends on vitamin D. Not only is the sun vital for vitamin D production, but it also exposes you to infrared light. Infrared reverses mitochondrial damage and can increase vitamin D signaling, further protecting you from a TB infection. Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

Contraception is designed to prevent untended pregnancies. Unintended pregnancies account for the majority of abortions. So it would seem that contraception reduces the number of abortions and that birth control is a blessing. But is that true? It's a disputed matter—especially among pro-lifers. On this episode of The 40 Days for Life Podcast, we answer the question: Is contraception a blessing or a curse? NOTE: On this episode, we discuss Dr. Edward Green's explanation of the concept of risk compensation. Dr. Green describes the phenomenon using the examples of HIV and sun exposure. We apply the principle to contraception and pregnancy. See this interview for more information: bbc.co.uk/blogs/ni/2009/03/aids_expert_who_defended_the_p.html

In the 1980s, the tiny town of Arcadia, Florida, was “fifty miles and fifty years from Sarasota.” With its cowboy roots, low-wage agricultural industries, and violent frontier history, Arcadia was a curious mix of the desolate ranchlands of West Texas and the stately homes and bitter race relations of the South. In A Town without Pity, award-winning author Jason Vuic recounts two heartbreaking stories from Arcadia that rose to national prominence at the end of the Reagan era and forced the town to reckon with not only AIDS hysteria but also the legacies of a racist past. This book delves into the case of James Richardson, a Black migrant worker accused in 1967 of poisoning his seven children. Richardson spent twenty years in prison due to suppressed evidence for a crime he didn't commit. Vuic also tells the story of the public mistreatment of the three Ray brothers, white school-age children with hemophilia who contracted the HIV virus from a tainted medicine called factor VIII. The Rays were barred from attending their local church and school, and when their house burned down in a mysterious arson, reporters dubbed Arcadia the “town without pity.”Through extensive use of newspapers, court records, and interviews, Vuic shows how the actions of authorities and residents left little room for the voices that spoke up against bias, harassment, and coercion. At the same time, this cautionary tale places Arcadia as a microcosm of many small towns in the late twentieth-century United States, reminding readers of the staying power of social divisions and prejudice even after the achievements of the civil rights movement. A TOWN WITHOUT PITY: AIDS, Race, and Resistance in Florida's Deep South—Jason Vuic

Friday, October 27th, 2023In the Hot Notes: at least 18 people are dead and another 13 injured after shootings in Lewiston Maine; New York Republicans push ahead with a resolution to expel George Santos from the House; NRA revenue is in free-fall after dues and membership plummet; A federal judge has struck down Georgia's congressional and legislative maps ruling that they violate Section 2 of the Voting Rights Act; Ford and the United Auto Workers Union have reached a tentative deal that includes a record pay raise; Republicans delay more than $1B in HIV program funding; a former healthcare executive is charged for a multi-million dollar Medicare fraud scheme; the DoJ responds to Trump's motions to stay his DC gag order and to alert the court of his advice of counsel defense; the US economy grew at a blistering rate in the third quarter; the Ohio secretary of state has quietly removed 26,000 people from voter rolls; plus Allison delivers your Good News.Dana is out and about.More from our Guest:Anna Bowerhttps://twitter.com/annabowerhttps://www.lawfaremedia.orgSubscribe to Lawyers, Guns, And Money:Ad-free premium feed:https://lawyersgunsandmoney.supercast.comSubscribe for free everywhere else:https://link.chtbl.com/LawGunsMoney Our Donation LinksNational Security Counselors - DonateMSW Media, Blue Wave California Victory Fund | ActBlueWhistleblowerAid.org/beansFederal workers - feel free to email AG at fedoath@pm.me and let me know what you're going to do, or just vent. I'm always here to listen. Find Upcoming Actions 50501 Movement, No Kings.org, Indivisible.orgDr. Allison Gill - Substack, BlueSky , TikTok, IG, TwitterDana Goldberg - BlueSky, Twitter, IG, facebook, danagoldberg.comCheck out more from MSW Media - Shows - MSW Media, Cleanup On Aisle 45 pod, The Breakdown | SubstackShare your Good News or Good TroubleMSW Good News and Good TroubleHave some good news; a confession; or a correction to share?Good News & Confessions - The Daily Beanshttps://www.dailybeanspod.com/confessional/ Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:The Daily Beans on Apple PodcastsWant to support the show and get it ad-free and early?The Daily Beans | SupercastThe Daily Beans & Mueller, She Wrote | PatreonThe Daily Beans | Apple Podcasts Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.